for the P2B Study Group. Double-Blind Study comparing P2B001 (combination of low-doses of extended-release Pramipexole and Rasagiline) to components and to optimised doses of Pramipexole-extended release in early Parkinson’s Disease. | USF Parkinson's Disease and Movement Disorders Center

Hauser, RA, CW Olanow, D Burdick, R Dhall, JA de Marcaida, RA Gil, DL Kreitzman, L Elmer, A McGarry, and K Kieburtz. 2024. “For the P2B Study Group. Double-Blind Study Comparing P2B001 (combination of Low-Doses of Extended-Release Pramipexole and Rasagiline) to Components and to Optimised Doses of Pramipexole-Extended Release in Early Parkinson’s Disease.”. . Mov Disord. 2024 Feb;39(2):350-359. Doi: 10.1002/Mds.29642. Epub 2023 Oct 27. PMID: 37886872.

Last updated on 09/06/2024